Table 2 Ongoing clinical trials targeting B7-H3
From: Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy
Trial number | Intervention | Intervention type | Phase | Status | Cancer type |
|---|---|---|---|---|---|
NCT04145622 | DS-7300a | B7-H3 ADC | I/II | Recruiting | Advanced solid tumors |
NCT05280470 | DS-7300a | B7-H3 ADC | II | Recruiting | Extensive-stage small cell lung cancer |
NCT03729596 | MGC018/ MGA012 | Anti-B7-H3 ADC with Anti-PD-1 Ab | I/II | Recruiting | 6 advanced solid tumors |
NCT02192567 | DS-5573a | B7-H3 ADCC | I | Terminated | Advanced solid tumors |
NCT01391143 | MGA271 | B7-H3 ADCC | I | Completed | Prostate cancer, melanoma, renal cell carcinoma, triple-negative breast cancer, head and neck cancer, bladder cancer and NSCLC |
NCT02982941 | MGA271 | B7-H3 ADCC | I | Completed | Solid tumor |
NCT02923180 | MGA271 | B7-H3 ADCC | II | Active, not recruiting | Prostate cancer |
NCT02381314 | MGA271/Ipilimumab | Anti-B7-H3 ADCC with Anti-CTLA-4 Ab | I | Completed | Melanoma and NSCLC |
NCT04630769 | MGA271/ FT516 and IL2 | Anti-B7-H3 ADCC with NK cell enhancing | I | Recruiting | Ovarian cancer |
NCT04634825 | MGA271/MGA012/MGD013 | Anti-B7-H3 ADCC with Anti-PD-1 Ab or PD-1 X LAG-3 BiAb | II | Terminated | Head and neck cancer |
NCT02475213 | MGA271/pembrolizumab/MGA 012 | Anti-B7-H3 ADCC with Anti-PD-1 Ab | I | Completed | Melanoma, head and neck cancer, NSCLC, urothelial carcinoma |
NCT02628535 | MGD009 | B7-H3 X CD3 BiAb | I | Terminated | Mesothelioma and 11 other cancers |
NCT03406949 | MGD009/ MGA012 | B7-H3 CD3 BiAb with Anti-PD-1 Ab | I | Active not recruiting | Advanced solid tumors |
NCT04432649 | 4SCAR-276 | CAR T cells | I/II | Recruiting | Solid tumor |
NCT05143151 | CD276 CAR-T | CAR T cells | I/II | Recruiting | Advanced pancreatic carcinoma |
NCT04637503 | Combined 4SCAR-276 | CAR T cells | I/II | Recruiting | Neuroblastoma |
NCT04864821 | B7-H3 CAR-T | CAR T cells | I | Not yet recruiting | 4 solid tumors |
NCT04185038 | SCRI-CARB7H3 | CAR T cells | I | Recruiting | Central nervous system tumors |
NCT04691713 | B7-H3 CAR-T | CAR T cells | Not applicable | Recruiting | Solid tumor |
NCT04385173 | B7-H3 CAR-T | CAR T cells | I | Recruiting | Recurrent/refractory glioblastoma |
NCT04670068 | B7-H3 CAR-T | CAR T cells | I | Recruiting | Recurrent epithelial ovarian cancer |
NCT04483778 | 4-1BBζ B7H3-EGFRt-DHFR | CAR T cells | I | Recruiting | Recurrent/refractory solid tumors |
NCT04077866 | B7-H3 CAR-T | CAR T cells | I/II | Recruiting | Recurrent/refractory glioblastoma |
NCT05241392 | B7-H3 CAR-T | CAR T cells | I | Recruiting | Glioblastoma |
NCT04897321 | B7-H3 CAR-T | CAR T cells | I | Recruiting | Pediatric solid tumor |
NCT05211557 | fhB7-H3 CAR-T | CAR T cells | I/II | Recruiting | Recurrent ovarian cancer |
NCT03198052 | B7-H3 and 10 other CAR-T | CAR T cells | I | Recruiting | Lung cancer |
NCT04842812 | B7-H3 and 11 other engineered CAR-T | CAR T cells | I | Recruiting | Advanced solid tumors |
NCT05190185 | TAA06 | CAR T cells | I | Recruiting | Malignant melanoma, lung cancer, or colorectal cancer |
NCT04692948 | TAA06 | CAR T cells | Not applicable | Recruiting | Acute myeloid leukemia |
NCT01502917 | 124I-omburtamab | Radioimmunotherapy | I | Terminate | Brain cancer |
NCT00089245 | 131I-omburtamab | Radioimmunotherapy | I | Active, not recruiting | Neuroblastoma, sarcoma and CNS tumors |
NCT01099644 | 131I-omburtamab | Radioimmunotherapy | I | Active, not recruiting | Peritoneal cancer |
NCT03275402 | 131I-omburtamab | Radioimmunotherapy | II/III | Recruiting | Neuroblastoma, CNS and leptomeningeal metastases |
NCT05063357 | 131I-omburtamab | Radioimmunotherapy | I | Not yet recruiting | Diffuse intrinsic pontine glioma |
NCT04022213 | 131I-omburtamab | Radioimmunotherapy | II | Recruiting | Peritoneum solid tumors |
NCT04743661 | 131I-omburtamab | Radioimmunotherapy | II | Active, not recruiting | Recurrent medulloblastoma and ependymoma |
NCT04315246 | 177Lu-DTPA-omburtamab | Radioimmunotherapy | I/II | Recruiting | Leptomeningeal metastasis solid tumor |
NCT04167618 | 177Lu-DTPA-omburtamab | Radioimmunotherapy | I/II | Recruiting | Medulloblastoma |